99mTc-3PRGD2 for integrin receptor imaging of lung cancer: A multicenter study

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 716-722

  Zhu, Zhaohui ^a   Miao, Weibing ^b   Li, Qianwei ^c   Dai, Haojie ^d   Ma, Qingjie ^e   Wang, Feng ^f   Yang, Aiming ^g   Jia, Bing ^h   Jing, Xiaona ^a   Liu, Sha ^a   Shi, Jiyun ^h   Liu, Zhaofei ^h   Zhao, Zhoushe ⁱ   Wang, Fan ^h   Li, Fang ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e JILIN UNIVERSITY   (China)

^f First Hospital of Nanjing   (China)

^g XI'AN JIAOTONG UNIVERSITY   (China)

^h PEKING UNIVERSITY   (China)

ⁱ GE HEALTHCARE   (China)

Author keywords

99mTc 3PRGD2; Integrin V 3; Lung cancer; Multicenter study; SPECT

Indexed keywords

3PRGD2 TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CYCLOPEPTIDE; DIAGNOSTIC AGENT; TECHNETIUM 99M (HYNIC 3PRGD(2))(TRICINE)(TPPTS); TECHNETIUM 99M (HYNIC-3PRGD(2))(TRICINE)(TPPTS); TECHNETIUM COMPLEX;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BONE METASTASIS; CALCULATION; CANCER DIAGNOSIS; CHRONIC INFLAMMATION; CLINICAL EVALUATION; CONSENSUS; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; IMAGE ANALYSIS; LUNG; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG LESION; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM; METASTASIS; MULTICENTER STUDY; NECROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; THORAX SCINTISCANNING; WHOLE BODY SCINTISCANNING; CLINICAL TRIAL; LUNG TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84860736140     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.098988     Document Type: Article

References (28)

1. Hynes RO. Integrins: A family of cell surface receptors. Cell. 1987;48:549-554.
2. Horton MA. The aVb3 integrin "vitronectin receptor." Int J Biochem Cell Biol. 1997;29:721-725.
3. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem. 2000;275:21785-21788. (Pubitemid 30621742)
4. Eliceiri BP, Cheresh DA. The role of alpha v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1227-1230. (Pubitemid 29218291)
5. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin aVb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
6. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491-497. (Pubitemid 17147032)
7. Haubner R,Wester HJ, Reuning U, et al. Radiolabeled aVb3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061-1071. (Pubitemid 29269229)
8. Haubner R, Wester HJ, Weber WA, Schwaiger M. Radiotracer based strategies to image angiogenesis. Q J Nucl Med. 2003;47:189-199. (Pubitemid 37279155)
9. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated aVb3 integrin in cancer patients by positron emission tomography and [18F] galacto-RGD. PLoS Med. 2005;2:-70.
10. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of aVb3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785. (Pubitemid 32691983)
11. Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the aVb3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341. (Pubitemid 43733484)
12. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F] galacto-RGD identifies the level of integrin aVb3 expression in man. Clin Cancer Res. 2006;12:3942-3949. (Pubitemid 44078079)
13. McParland BJ, Miller MP, Spinks TJ, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med. 2008;49:1664-1667.
14. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886. (Pubitemid 351793427)
15. Indrevoll B, Kindberg GM, Solbakken M, et al. NC-100717: A versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett. 2006;16: 6190-6193. (Pubitemid 44709917)
16. Bach-Gansmo T, Danieleeon R, Saracco A, et al. Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med. 2006;47:1434-1439. (Pubitemid 47544928)
17. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ. Study Group. An open-label, multi-center, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the aVb3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol. 2010;51:40-46.
18. Shi J, Wang L, Kim YS, et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimmers with triglycine linkers. J Med Chem. 2008;51:7980-7990.
19. Liu Z, Jia B, Shi J, et al. Tumor uptake of the RGD dimeric probe 99mTc-G3-2P4-RGD2 is correlated with integrin aVb3 expressed on both tumor cells and neovasculature. Bioconjug Chem. 2010;21:548-555.
20. Zhou Y, Kim YS, Chakraborty S, Shi J, Gao H, Liu S. 99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin aVb3 expression. Mol Imaging. 2011;10:386-397.
21. Jia B, Liu Z, Zhu Z, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin aVb3-selective radiotracer 99mTc-3PRGD2 in non-human primates. Mol Imaging Biol. 2011;13:730-736.
22. Ma Q, Ji B, Jia B, et al. Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy. Eur J Nucl Med Mol Imaging. 2011;38: 2145-2152.
23. Janssen M, Oyen W, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor imaging. Cancer Biother Radiopharm. 2002;17:641-646. (Pubitemid 36025945)
24. Dijkgraaf I, Kruijtzer JA, Liu S, et al. Improved targeting of the aVb3 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging. 2007;34:267-273. (Pubitemid 46147510)
25. Thumshirn G, Hersel U, Goodman SL, et al. Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry. 2003;9:2717-2725.
26. Chen X, Park R, Shahinian AH, et al. Pharmacokinetics and tumor retention of 125Ilabeled RGD peptide are improved by PEGylation. Nucl Med Biol. 2004;31:11-19. (Pubitemid 38115121)
27. Pichler BJ, Kneilling M, Haubner R, et al. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J Nucl Med. 2005;46:184-189. (Pubitemid 43086015)
28. McDonald DM, Choyke PL. Imaging of angiogenesis: From microscope to clinic. Nat Med. 2003;9:713-725. (Pubitemid 36749220)